[A17-44] Alectinib (non-small-cell lung cancer) - Addendum to commission A17-19
Last updated 19.10.2017
Project no.:
A17-44
Commission:
Commission awarded on 04.09.2017 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Advanced ALK-positive NSCLC (lung cancer)
Result of dossier assessment:
Hint of considerable added benefit for crizotinib and chemotherapy-pretreated adults who are eligible for treatment with docetaxel or pemetrexed
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A17-19 | Alectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2017-10-19 A G-BA decision was published.